Header Logo

Connection

HASHEM EL-SERAG to Proton Pump Inhibitors

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Proton Pump Inhibitors.
HASHEM EL-SERAG
Connection Strength
5.639
Proton Pump Inhibitors
  1. Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies. Dig Dis Sci. 2023 09; 68(9):3732-3744.
    View in: PubMed
    Score: 0.676
  2. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
    View in: PubMed
    Score: 0.560
  3. Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin. Nat Rev Clin Oncol. 2018 12; 15(12):728-730.
    View in: PubMed
    Score: 0.491
  4. Is Proton Pump Inhibitor Use Associated With Risk of Myocardial Infarction? Gastroenterology. 2016 Feb; 150(2):526-7.
    View in: PubMed
    Score: 0.400
  5. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
    View in: PubMed
    Score: 0.346
  6. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011 Sep; 34(6):618-27.
    View in: PubMed
    Score: 0.295
  7. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011 Apr; 33(7):829-36.
    View in: PubMed
    Score: 0.286
  8. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010 Sep; 32(6):720-37.
    View in: PubMed
    Score: 0.277
  9. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun; 138(7):2260-6.
    View in: PubMed
    Score: 0.267
  10. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009 Sep; 104(9):2161-7.
    View in: PubMed
    Score: 0.256
  11. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther. 2008 Jun; 27(12):1293-9.
    View in: PubMed
    Score: 0.234
  12. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007 Mar; 150(3):262-7, 267.e1.
    View in: PubMed
    Score: 0.217
  13. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004 Oct; 99(10):1877-83.
    View in: PubMed
    Score: 0.184
  14. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003 May 15; 17(10):1229-36.
    View in: PubMed
    Score: 0.167
  15. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001 Apr; 96(4):979-83.
    View in: PubMed
    Score: 0.144
  16. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.132
  17. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.119
  18. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.093
  19. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
    View in: PubMed
    Score: 0.085
  20. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.083
  21. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012 Jul; 36(1):3-15.
    View in: PubMed
    Score: 0.078
  22. Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System. Helicobacter. 2025 Mar-Apr; 30(2):e70034.
    View in: PubMed
    Score: 0.047
  23. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther. 2004 Jun 15; 19(12):1255-60.
    View in: PubMed
    Score: 0.045
  24. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. J Gastroenterol. 2022 12; 57(12):942-951.
    View in: PubMed
    Score: 0.040
  25. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002 Oct 14; 162(18):2105-10.
    View in: PubMed
    Score: 0.040
  26. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021 07 29; 7(1):55.
    View in: PubMed
    Score: 0.037
  27. Symptomatic reflux disease: the present, the past and the future. Gut. 2014 Jul; 63(7):1185-93.
    View in: PubMed
    Score: 0.022
  28. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1299-304.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.